亚搏手机足球_中国有限公司

Introduction

About YanengBIO

Leading the Molecular Diagnostics Market in China for 22 years.


Since 2001, Yaneng BIOscience (Shenzhen) Co., Ltd. developed the first gene chip in China, YanengBIO has taken the leading position in the Molecular diagnostics market in China through 22 years of development and continuous innovation. YanengBIO have established the leading position in the Molecular diagnostics market in China. At present, the company has about 600 employees, among which the R&D department led by Ph.D team accounts for more than 20%.

At present, our core products, HPV and Thalassemia projects, have occupied No.1 place in the Chinese market, with sales revenue CAGR of 24% and annual R&D expenditure 18%.

30000000

HPV Product testing

13000000

Thalassemia gene product testing

70000000

MNP product sales

Data as of 20 October 2021

Corporate Culture

Mission

Mission

Develop Molecular Diagnostics,and Benefit Human Health.

Vision

Vision

R&D can make every laboratory enjoy the finest service brought by high-quality IVD products.

Value

Value

Innovation drives R&D, works with agility.

Talent Team

Professional & Brilliant teams

Professional & Brilliant teams

11 PhDs, 5 talents of Peacock Plan.
R&D technicians accounted for 1/5.
Undergraduate or above employees accounted for 50%.
Average age of the team is 32 years old.

Three major R&D technology centers

Three major R&D technology centers

Enterprise postdoctoral workstation.
Tumor liquid biopsy technological service platform.
Gene chip engineering research center.

2021 发展
DEVELOP

2021

Probably the BEST HPV-test 2021

  • No.1 in national HPV EQA results for 5 years

  • Sail to overseas

2020 发展
DEVELOP

2020

Development & Expansion 2020

Shenzhen's first enterprise Postdoctoral Workstation

Establish Province HPV Gene Chip R&D Center

HPV vaccine clinical research designated product

2019 发展
DEVELOP

2019

Social Responsibility 2019

Social Responsibility Award of "China Cervical Cancer Prevention and Control Project".

2010-2016 发展
DEVELOP

2010-2016

Optimized Quality 2010-2016

Join FOSUN Pharma 2010
No.1 HPV & Thalassemia market share in China
100% passed the national HPV EQA
Design Thalassemia national standard

 

2004-2007 发展
DEVELOP

2004-2007

Recognized 2004-2007

Member of the WHO Cervical Cancer Screening Program
ISO13485

2002-2003 发展
DEVELOP

2002-2003

First Step 2002-2003

ISO9001
Developed China's first gene chip

2001 发展
DEVELOP

2001

Established in 2001

2021

2020

2019

2010-2016

2004-2007

2002-2003

2001

Honor

ISO
ISO
CE
CE
Postdoctoral Workstation
Postdoctoral Workstation
HI-TECH Enterprise
HI-TECH Enterprise
National Social Responsibility Award
National Social Responsibility Award
EAR
EAR
Honorary Certificate

Global


Contact Us

Baidu
sogou